The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)

Journal of Clinical Pharmacology

Volumn 39, Issue 11, 1999, Pages 1155-1161

  Zimmerman, J J ^a   Ferron, G M ^a   Lim, H K ^a   Parker, V ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIETARY INTAKE; DRUG BIOAVAILABILITY; FAT INTAKE; FEMALE; FOOD DRUG INTERACTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; NORMAL HUMAN; ORGAN TRANSPLANTATION;

EID: 0033346578     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009903901107     Document Type: Article

References (34)

1. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle
2. Identification of a new pharmacologic action for an old compound
3. Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides
4. Rapamycin (sirolimus, rapamune)
5. New immunosuppressive drugs in organ transplantation
6. Rapamycin: FK506's fraternal twin or distant cousin?
7. Immunosuppressants: Cellular and molecular mechanisms of action
8. The three fates of immunosuppression in the next millennium: Selectivity, synergy, and specificity
9. Population pharmacokinetics of sirolimus in kidney transplant patients
10. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
11. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
12. Isolation of two immunosuppressive metabolites after in-vitro metabolism of rapamycin
13. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype
14. Human P-glycoprotein transports cyclosporin A and FK506
15. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450 III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
16. Affect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients
17. Diet and cyclosporine A: Pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules
18. Active secretion and enterocytic drug metabolism barriers to drug absorption
19. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation
20. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
21. Bio-International '92, Conference on Bioavailability, bioequivalence and pharmacokinetic studies
22. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/ electrospray-mass spectrometry
23. Effects of food on drug absorption
24. The effects of food on drug bioavailability
25. Interactions affecting drug absorption
26. The influence of food on the absorption and metabolism of drugs: An update
27. The clinical significance of food-drug interactions: A review
28. Effects of dietary fat on drug absorption
29. Interactions between drugs and nutrients
30. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
31. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)